BioInvent International AB (publ) (BOVNF)
BOVNF Stock Price Chart
Explore BioInvent International AB (publ) interactive price chart. Choose custom timeframes to analyze BOVNF price movements and trends.
BOVNF Company Profile
Discover essential business fundamentals and corporate details for BioInvent International AB (publ) (BOVNF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Sept 2013
Employees
114.00
Website
https://www.bioinvent.comCEO
Martin Welschof
Description
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
BOVNF Financial Timeline
Browse a chronological timeline of BioInvent International AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 29 Oct 2025
Earnings released on 26 Aug 2025
Earnings released on 29 Apr 2025
EPS came in at -$1.78 , while revenue for the quarter reached $22.06M .
Earnings released on 27 Feb 2025
EPS came in at -$1.78 , while revenue for the quarter reached $21.37M .
Earnings released on 31 Oct 2024
EPS came in at -$1.48 , while revenue for the quarter reached $12.76M .
Earnings released on 29 Aug 2024
EPS came in at -$2.09 , while revenue for the quarter reached $4.61M .
Earnings released on 24 Apr 2024
EPS came in at -$1.18 , while revenue for the quarter reached $5.94M .
Earnings released on 22 Feb 2024
EPS came in at -$1.48 falling short of the estimated -$0.11 by -1.25K%, while revenue for the quarter reached $15.32M , beating expectations by +1.62K%.
Earnings released on 30 Sept 2023
EPS came in at -$1.08 falling short of the estimated -$0.11 by -855.25%, while revenue for the quarter reached $26.80M , beating expectations by +3.57K%.
Earnings released on 30 Jun 2023
EPS came in at -$1.34 falling short of the estimated -$0.12 by -1.05K%, while revenue for the quarter reached $13.10M , beating expectations by +1.48K%.
Earnings released on 31 Mar 2023
EPS came in at -$0.90 falling short of the estimated -$0.12 by -642.47%, while revenue for the quarter reached $16.25M , beating expectations by +2.02K%.
Earnings released on 22 Feb 2023
EPS came in at -$1.21 surpassing the estimated -$1.25 by +3.20%, while revenue for the quarter reached $20.64M , beating expectations by +2.80K%.
Earnings released on 27 Oct 2022
EPS came in at -$1.00 surpassing the estimated -$1.17 by +14.53%, while revenue for the quarter reached $17.92M , beating expectations by +2.34K%.
Earnings released on 24 Aug 2022
EPS came in at $2.86 surpassing the estimated -$1.16 by +346.55%, while revenue for the quarter reached $270.91M , beating expectations by +8.33K%.
Earnings released on 27 Apr 2022
EPS came in at -$1.16 surpassing the estimated -$1.67 by +30.54%, while revenue for the quarter reached $16.66M , beating expectations by +375.35%.
Earnings released on 23 Feb 2022
EPS came in at -$1.35 surpassing the estimated -$1.37 by +1.46%, while revenue for the quarter reached $4.90M , missing expectations by -17.65%.
Earnings released on 27 Oct 2021
EPS came in at -$1.07 surpassing the estimated -$1.71 by +37.43%, while revenue for the quarter reached $2.99M .
Earnings released on 26 Aug 2021
EPS came in at -$0.98 surpassing the estimated -$1.13 by +13.27%, while revenue for the quarter reached $5.29M .
Earnings released on 28 Apr 2021
EPS came in at -$1.94 , while revenue for the quarter reached $6.20M .
Earnings released on 23 Feb 2021
EPS came in at $0.87 , while revenue for the quarter reached $98.74M .
Stock split effective on 20 Jan 2021
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 14 Dec 2020
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 29 Oct 2020
EPS came in at -$1.00 , while revenue for the quarter reached $16.27M .
BOVNF Stock Performance
Access detailed BOVNF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.